Express Scripts sales grow as Trump weighs upending business model

Published



Express Scripts revenue surged in the three months through September, even as speculation mounted that the Trump administration will try to revamp a key piece of its business model.

Sales at the pharmacy benefit manager, which earlier this year won federal approval for its merger with Cigna, grew to $25.6 billion. Profit rose 27 percent to $1.1 billion, or $1.89 a share.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.